Consolidated results for the first quarter of the fiscal year ending December 2026
SymBio Pharmaceuticals Limited and its group companies
TREAKISYN® IV infusion 100 mg/4 mL [RTD (Ready-To-Dilute) formulation], BCV (brincidofovir), and the IVD business
Revenue from TREAKISYN declined due to the impact of a drug price revision and the growing penetration of generic products. Research and development expenses also increased as research and development activities for the global Phase III clinical trial targeting adenovirus infection after hematopoietic stem cell transplantation entered full-scale operation.
Revenue: ¥233,463 thousand; operating loss: ¥2,341,115 thousand; ordinary loss: ¥2,390,608 thousand; quarterly net loss attributable to owners of the parent: ¥2,401,405 thousand (first quarter of the fiscal year ending December 2026)
First quarter of the fiscal year ending December 2026 (1 January 2026–31 March 2026)
The consolidated earnings forecast for the fiscal year ending December 2026 is unchanged from the forecast announced on 5 February 2026. The full-year forecast is revenue of ¥3,891 million, an operating loss of ¥4,231 million, an ordinary loss of ¥4,291 million, and a net loss attributable to owners of the parent of ¥4,331 million.
Company response
The international joint Phase Ib clinical trial targeting patients with malignant lymphoma is currently on temporary hold.
The company will continue clinical development of BCV, research and development for multiple indications, early commercialization of the IVD business, securing funding through equity financing and other means, collaboration and business alliances with other companies, cost management and expense reductions, and optimization of its fixed-cost structure. However, uncertainty remains regarding the progress of research and development, the success of partnering and business alliances, and the funding environment.
| Item | Details |
|---|---|
| Event name | Consolidated results for the first quarter of the fiscal year ending December 2026 |
| Date of occurrence | 31 March 2026 (end of the first-quarter consolidated accounting period) |
| Subject Entity | SymBio Pharmaceuticals Limited and its group companies |
| Target Locations / Products | TREAKISYN® IV infusion 100 mg/4 mL [RTD (Ready-To-Dilute) formulation], BCV (brincidofovir), and the IVD business |
| Cause | Revenue from TREAKISYN declined due to the impact of a drug price revision and the growing penetration of generic products. Research and development expenses also increased as research and development activities for the global Phase III clinical trial targeting adenovirus infection after hematopoietic stem cell transplantation entered full-scale operation. |
| Amount of Impact on Business Performance | Revenue: ¥233,463 thousand; operating loss: ¥2,341,115 thousand; ordinary loss: ¥2,390,608 thousand; quarterly net loss attributable to owners of the parent: ¥2,401,405 thousand (first quarter of the fiscal year ending December 2026) |
| Accounting period in which recognized | First quarter of the fiscal year ending December 2026 (1 January 2026–31 March 2026) |
| Impact on Earnings Forecast | The consolidated earnings forecast for the fiscal year ending December 2026 is unchanged from the forecast announced on 5 February 2026. The full-year forecast is revenue of ¥3,891 million, an operating loss of ¥4,231 million, an ordinary loss of ¥4,291 million, and a net loss attributable to owners of the parent of ¥4,331 million. |
| Suspended operations | The international joint Phase Ib clinical trial targeting patients with malignant lymphoma is currently on temporary hold. |
| Outlook | The company will continue clinical development of BCV, research and development for multiple indications, early commercialization of the IVD business, securing funding through equity financing and other means, collaboration and business alliances with other companies, cost management and expense reductions, and optimization of its fixed-cost structure. However, uncertainty remains regarding the progress of research and development, the success of partnering and business alliances, and the funding environment. |
Items this document does not state (15)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue from TREAKISYN declined due to the impact of a drug price revision and the growing penetration of generic products. Research and development activities for the global Phase III clinical trial targeting adenovirus infection after hematopoietic stem cell transplantation entered full-scale operation, resulting in higher research and development expenses. The company also explains that its research and development-driven business requires substantial research and development expenses and considerable time before products can be commercialized and generate revenue.